



INTERNATIONAL CONGRESS OF THE
EGYPTIAN
OPHTHALMOLOGICAL SOCIETY

In collaboration with:



MEACO
MIDDLE EAST AFRICA
COUNCIL OF OPHTHALMOLOGY

Implantable Collamer Lens (ICL) Surgery

Dr. Georgios Roussopoulos, MD, PhD

Director of HYPERVISION Ophthalmology Clinic
Athens, Greece



Disclosure for Dr. Georgios P. Roussopoulos

In compliance with COI policy, ESCRS requires the following disclosures to the session audience:

Shareholder	No relevant conflicts of interest to declare.
Grant / Research Support	Théa
Consultant	Rafarm
Employee	No relevant conflicts of interest to declare.
Paid Instructor	Alcon, Bausch and Lomb
Speaker Bureau	Alcon, Bausch and Lomb
Other	Cooper, Erghani, Kite and Vianex

Presentation includes discussion of the following off-label use of a drug or medical device:


None



EYE CLINIC

Dr Georgios Roussopoulos

HYPERVISION  N



Introduction: Why ICL?

- Rising global prevalence of myopia and astigmatism
- Increasing demand for refractive surgery
- ICL: A valuable alternative to corneal refractive procedures (LASIK/PRK)
- Suitable for patients with high ametropia or thin corneas

What is an Implantable Collamer Lens (ICL)?

- A phakic intraocular lens (pIOL) placed between the iris and crystalline lens
- Made from Collamer: a biocompatible, collagen-copolymer material
- Offers UV protection and excellent optical clarity
- Preserves natural accommodation

Types of ICLs

- EVO Visian ICL
- EVO+ Visian ICL (enhanced size range)
- Toric ICL (TICL) for astigmatism
- Central Port (KS-AquaPORT) design: eliminates pre-op iridotomy

Safety of EVO ICL

Eyes (n)	4196
Follow Up	Up to 5 years*
Weighted Average Safety Index	1.15
Visually Significant ASC	0.00% (n=0)
ECL	-2.6%
Pupillary Block	0.04% (n=1)**
Pigment Dispersion	0.00% (n=0)
Secondary Surgical Intervention	0.47% (n=14)***

ASC: Anterior subcapsular cataract / ECL: Endothelial cell loss

1. Packer, M. The Implantable Collamer Lens with a central port: review of the literature. Clinical Ophthalmology 2018;12 2427–2438.

EGYPTIAN OPHTHALMOLOGICAL SOCIETY



* weighted average 14 months

** due to retained viscoelastic (N=2517)

*** N = 2970

Indications & Patient Selection

- Moderate to high myopia (-3.0D to -20.0D)
- Hyperopia (+3.0D to +10.0D)
- Astigmatism (up to 6.0D with Toric ICL)
- Age: 21-45 years
- Anterior chamber depth ≥ 2.8 mm
- Stable refraction ≥ 1 year
- Good endothelial cell count

Contraindications

- Anterior chamber depth < 2.8 mm
- Endothelial cell density below safety limits
- History of glaucoma or uveitis
- Pregnancy/lactation
- Unstable refraction
- Unrealistic patient expectations

Preoperative Assessment



- Refraction (subjective & cycloplegic)
- Corneal topography & pachymetry
- Anterior chamber depth measurement
- White-to-white distance
- Endothelial cell count
- Dilated fundus exam

ICL Sizing & Power Calculation

- Accurate sizing crucial for optimal vault
- Based on WTW & ACD
- Software-assisted calculation

Diagnostic Imaging in ICL Assessment

- Modalities: Anterior segment OCT, specular microscopy, UBM
- Benefits: Accurate measurement of ICL vault and corneal health



Anterior Segment OCT

- Visualizes ICL position, vault, and angle anatomy
- Helps prevent complications like pupillary block





Fig. 1 Examples of the ANTERION result pages for anterior segment measurements

Specular Microscopy

- Monitors corneal endothelial cell density
- Regular examinations ensure long-term health

Figure 3. Endothelial cell density (ECD) measurement in a patient with a very low ECD. An automatic measurement (a) overestimated the ECD (674 cells/mm²) as the algorithm did not recognize the cell boundaries correctly. Using the same image, manual measurements using the center method (b) and the corner method (c) resulted in lower ECD values (473 cells/mm² and 482 cells/mm², respectively).



1. Naujokaitis T, Auffarth GU, Łabuz G, Kessler LJ, Khoramnia R. Diagnostic Techniques to Increase the Safety of Phakic Intraocular Lenses. *Diagnostics (Basel)*. 2023;13(15):2503. doi:10.3390/diagnostics13152503

UBM

- Preoperative and postoperative analysis

Descriptive Analysis of Footplate Position After Myopic Implantable Collamer Lens Implantation Using a Very High-Frequency Ultrasound Robotic Scanner

Roger Zaldivar¹, Roberto Zaldivar¹, Pablo Adamek¹, Gabriel Quintero¹, Alejandro Cerviño^{1,2}

¹Instituto Zaldivar, Mendoza, Argentina; ²Department of Optics & Optometry & Vision Sciences, University of Valencia, Valencia, Spain

Correspondence: Alejandro Cerviño, Department of Optics & Optometry & Vision Sciences, University of Valencia, C/ Dr. Moliner, 50, Burjassot, Valencia, 46100, Spain. Tel: +34 963 544 052. Email: alejandro.cervino@uv.es




Figure 2 Images showing the ICL plate resting on the ciliary body (A) and the sulcus (B).

Results: In 81% of cases (42 eyes), the ICL rests on the ciliary body (CB) in both temporal and nasal sides, being slightly lower than 6% (3 eyes) those that rest on the sulcus in both sides, with significant correlations between ICL position and vault values ($p < 0.05$). Cases in which the ICL position was CB-CB yielded central vault values across the whole range determined within the sample, but most of the eyes where the ICL rests on both the sulcus in one side and the CB in the other yield greater central vault values. Correlation was significant between ICL position and retroposition distance on the temporal side (Spearman's rho -0.487 , $p < 0.001$). A significant but weaker correlation was also found between ICL position and retroiridian space ($p < 0.05$).

Importance of Post-Operative Monitoring

- Early detection is crucial
- Regular follow-up to check IOP, inflammation, and lens position

The Early Post-Operative Period (First 24 Hours)

- Key observations: IOP, inflammation, lens positioning
- Watch for IOP spikes and inflammation



INTERNATIONAL CONGRESS OF THE
EGYPTIAN
OPHTHALMOLOGICAL SOCIETY

In collaboration with:



MEACO
MIDDLE EAST AFRICA
COUNCIL OF OPHTHALMOLOGY

IOP Spikes



IOP Spikes – Definition & Incidence

- Definition: Significant rise in intraocular pressure post-op
- Causes: Retained viscoelastic, pupillary block, steroid response, excessive vault, TASS, UZS, Pigment dispersion syndrome, malignant glaucoma
- Relatively common if not managed properly

Causes and management strategies for elevated intraocular pressure after implantable collamer lens implantation

Di Gong^{1†}, Simin Deng^{2†}, Kuanrong Dang^{1†}, Zonghui Yan^{1*} and Jiantao Wang^{1*}

¹Shenzhen Eye Hospital, Jinan University, Shenzhen Eye Institute, Shenzhen, Guangdong, China, ²The 2nd Clinical Medical College (Shenzhen People's Hospital) of Jinan University, Shenzhen, China

EOS 2025

EGYPTIAN OPHTHALMOLOGICAL SOCIETY

22/06/2025

Intraocular pressure during the early postoperative period after 100 consecutive implantations of posterior chamber phakic intraocular lenses with a central hole

Felix Gonzalez-Lopez, MD, Rafael Bilbao-Calabuig, MD, Blas Mompean, MD, Victoria de Rojas, MD, PhD, Jorge Luezas, MD, Mohammad Raza Djodeyri, MD, PhD, Jaime Beltran, MD

PURPOSE: To study changes in intraocular pressure (IOP) during the early postoperative period in eyes having implantation of a posterior chamber phakic intraocular lens (pIOL) (Visian Implantable Collamer Lens V4c).

SETTING: Clinica Baviera, Instituto Oftalmológico Europeo, Madrid, Spain.

DESIGN: Case series.


METHODS: This retrospective review included the first consecutive eyes having implantation of a spherical or toric myopic pIOL, with a central hole at Clinica Baviera from December 2011 to June 2012 by the same experienced surgeon. The IOP was evaluated preoperatively and 1 day, 1 week, and 1 month postoperatively.

RESULTS: The study comprised 100 eyes. The mean IOP changed from 14.6 mm Hg \pm 3.4 (SD) (range 8 to 26 mm Hg) preoperatively to 14.5 \pm 4.6 mm Hg (range 6 to 30 mm Hg) 1 day postoperatively, 14.2 \pm 4.2 mm Hg (range 6 to 29 mm Hg) at 1 week, and 12.3 \pm 3.4 mm Hg (range 9 to 24 mm Hg) at 1 month. No statistically significant changes were detected over time postoperatively ($P > .2$). No perioperative complications associated with the implantation of the pIOL were recorded. No pIOLs were explanted, no toric pIOL rotation was detected, and no pupillary block or acute angle closure was observed.

CONCLUSION: The short-term clinical data for the new pIOL model with the central hole (KS-Aquaport) suggest that it is a safe and effective means for controlling postoperative IOP.

IOP Spike – Pathophysiology

- Mechanism: Residual OVD clogs the trabecular meshwork
- Effects: Corneal edema, eye pain, blurred vision



ETIOLOGIES OF ELEVATED IOP

Patient¹

- Age ²
- Myopia ^{2,3,7,8}
- History of ocular trauma
- Chronic iritis/Steroid response
- Gonioscopy
 - Narrow angles
 - Iris configuration
 - Pigment dispersion syndrome (young, myopic males) ²

Surgeon

- Inadequate preoperative iridotomies ^{1,2,5,6}
- Careful and thorough removal of viscoelastic

ICL⁴

- Excessive vault (>1000 µm)
 - Angle crowding to angle closure
 - Iris chaffing and pigment dispersion

1. Chen et al. Metaanalysis of cataract development after PIOL surgery. J Cataract Refract Surg 2008; 34:1181–1200.
2. Chun et al. iris and trabecular meshwork pigment changes after posterior chamber phakic IOL implantation. J Cataract Refract surg 2006; 32:1452-1458.
3. Xu L, Wang Y, Wang S, et al. High myopia and glaucoma susceptibility the Beijing Eye Study. Ophthalmology 2007;114:216–20.
4. Choi et al. Ultrasound biomicroscopy for determining Visian Icl length in phakic IOL implantation. J Refract Surg. 2007; 23:362-367.
5. Esteban et al. IOP after implantation of Visian ICL with CentraFLOW without iridotomy. Am J Ophthalmol 2013; 156:800-805.
6. McCaughey et al. Pseudophacomorphic glaucoma along with pupillary block after Visian ICL implantation in High Myopia. Open Journal of Ophthalmology. 4, 107-111
7. Wu SY, Nemesure B, Leske MC. Glaucoma and myopia. Ophthalmology 2000 Jun; 107(6):1026-7.
8. Ponte F, Giuffre G, Giammanco R, Dardanoni G. Risk Factors of ocular hypertension and glaucoma. The Casteldaccia Eye Study. Ophthalmol 1994; 85(3):203-10.

IOP Spike – Management Strategies

- Thorough removal of viscoelastic during surgery
- IOP-lowering medications
- Laser peripheral iridotomy (for older ICL models)
- Anterior chamber washout in severe cases

Thorough removal of viscoelastic during surgery
IOP-lowering medications
Laser peripheral iridotomy (for older ICL models)
Anterior chamber washout in severe cases

Causes	Clinical manifestation	Management strategies
Keratic epithelial debris/viscoelastic	Intolerable ocular pain and ocular epithelial lesions in the first 24h. Peak intraocular pressure (IOP) is usually 50 mmHg or higher, and residual viscoelastic in the anterior chamber can be observed by slit lamp.	<ol style="list-style-type: none"> 1. Surgeons can choose the IVD application method based on their own experience. 2. If the IOP is only mildly elevated, short-term application of osmotic hypotensive eye drops may be considered. 3. If the IOP exceeds 50 mmHg and continues to rise, it is advisable to continue to flushing the anterior chamber to thoroughly remove the remaining viscoelastic substances.
Severe response	IOP elevation usually occurs 1-2 weeks after surgery.	<ol style="list-style-type: none"> 1. The administration or replacement with a lower potency corticosteroid is recommended, accompanied by the topical application of glaucoma medications. 2. If the intraocular pressure continues to rise, further surgical treatment is required. The most common surgery is trabeculectomy, but implantation of a drainage device or other techniques may also be considered.
Excessive ICL vault	Corneal edema, anterior chamber shallowing, intraocular contact, and ongoing findings suggesting an vault > 90um can be observed after surgery.	<ol style="list-style-type: none"> 1. Preoperative measurement of various anterior segment parameters before surgery, and reasonable selection of ICL model. 2. If intraoperative OCT can be used during surgery. 3. Use slit lamp microscope and AS-OCT to observe the crystalline vault regularly after surgery. 4. Apply glaucoma medications to reduce IOP in a prompt period of time. 5. If the patient has a vault that is not a minor ICL, the vault can usually be lowered by rotating the lens in the vertical axis. 6. In cases of pupillary block glaucoma, laser iridotomy or iridectomy may be necessary, and if needed, the ICL should be promptly removed.
Endo anterior segment syndrome (EASS)	Averse manifestation within 12-48h after surgery, with the main symptoms including elevated IOP, corneal edema and other anterior segment inflammatory reactions.	<ol style="list-style-type: none"> 1. Excluding iridocyclitis and epithelialitis. 2. The main method is topical or systemic application of steroids. 3. The routine anterior chamber flushing should not be carried out, which may aggravate the damage of the anterior chamber.
Uveitis-like syndrome (ULS)	Early postoperative symptoms such as glare, pain and photophobia, signs such as increased intraocular pressure, pupil dilation and anterior chamber reaction to pupillary medication can be observed.	<ol style="list-style-type: none"> 1. Manual system use of drugs to reduce intraocular pressure. 2. Remove air or gas from the anterior chamber. 3. If necessary, iridectomy can be conducted to alleviate the closure of the anterior chamber angle.
Pigment dispersion syndrome (PDS)	Induced in the short-term postoperative period, may present with extreme photophobia, ocular pain, eye redness and blurred vision, with gas including the cornea, iris diameter 280° peripheral iris transillumination, increased pigment deposition in the trabecular meshwork, and pigment deposition on the corneal endothelium (Fleischer's ring-like).	<ol style="list-style-type: none"> 1. Detailed slit lamp examination to monitor signs of pigment dispersion. 2. IOP lowering and anti-inflammatory therapy should be performed as soon as PDS and secondary IOP elevation are present. 3. Consider removal of the ICL if necessary to reduce friction between the lens and the iris. 4. Filtration surgery is safe and effective in the treatment of pigmentary glaucoma.
Malignant glaucoma	Elevated IOP, corneal edema and anterior chamber deepening occurred in the early postoperative period.	<ol style="list-style-type: none"> 1. Include conditions such as pupil block, extremely high ICL vault, and suprachoroidal hemorrhage. 2. Pharmacological treatment is the first line of treatment for malignant glaucoma, including topical potent steroid eye drops, topical anti-inflammatory agents and aqueous humor inhibitors, as well as systemic hypotensive agents. 3. If conservative treatment is not effective, further surgical intervention is required, such as vitrectomy combined with iridotomy or iridectomy, with or without removal of the ICL.



INTERNATIONAL CONGRESS OF THE
EGYPTIAN
OPHTHALMOLOGICAL SOCIETY

In collaboration with:



MEACO
MIDDLE EAST AFRICA
COUNCIL OF OPHTHALMOLOGY

Inflammation



Inflammation – Etiology & Incidence

- Causes: Surgical trauma, residual contaminants
- Mild inflammation is common; severe TASS is rare

1. Cerqueira Silva AF, Ferreira Mendes JC, Dourado Araújo Leite RJ, Lopes Franqueira Pereira NF, Monteiro TPT. Phakic intraocular lens exchange due to severe uveitis/inflammation: case report. *JCRS Online Case Reports*. 2024;12(4):e00132. doi:10.1097/j.jcro.0000000000000132
2. Hernandez-Bogantes E, Ramirez-Miranda A, Olivo-Payne A, Abdala-Figuerola A, Navas A, Graue-Hernandez EO. Toxic anterior segment syndrome after implantation of phakic implantable collamer lens. *Int J Ophthalmol*. 2019;12(1):175-177. doi:10.18240/ijo.2019.01.27
3. Singh A, Gupta N, Kumar V, Tandon R. Toxic anterior segment syndrome following phakic posterior chamber IOL: a rarity. *BMJ Case Rep*. 2018;11(1):bcr-2018-225806. doi:10.1136/bcr-2018-225806
4. Mimouni M, Alió Del Barrio JL, Alió JL. Occlusion of AquaPORT Flow in a Case of Toxic Anterior Segment Syndrome Following Implantable Collamer Lens Surgery Causing Severe Pupillary Block. *J Refract Surg*. 2020;36(12):856-859. doi:10.3928/1081597X-20201015-01
5. Li L, Zhou Q. Late-onset toxic anterior segment syndrome after ICL implantation: two case reports. *BMC Ophthalmol*. 2023;23(1):61. doi:10.1186/s12886-022-02713-3
6. Qi H, Xie X, Zhang Q. Presumed atypical late-onset toxic anterior segment syndrome after implantable collamer lens implantation: a case report. *BMC Ophthalmol*. 2024;24(1):347. doi:10.1186/s12886-024-03615-2
7. Kong X, Xiang X, Huang Z, Lv H. Toxic anterior-segment syndrome induced by the cotton fiber after ICL implantation: A case report. *Asian J Surg*. 2024;47(8):3632-3634. doi:10.1016/j.asjsur.2024.04.062

Inflammation – Clinical Presentation & Grading

- Signs: Redness, pain, cells and flare in the anterior chamber
- Grading scales used to assess severity

Inflammation – Medical Management

- Treatment: Topical steroids and anti-inflammatory drops
- High-frequency dosing initially, then gradual taper



INTERNATIONAL CONGRESS OF THE
EGYPTIAN
OPHTHALMOLOGICAL SOCIETY

In collaboration with:



MEACO
MIDDLE EAST AFRICA
COUNCIL OF OPHTHALMOLOGY

Endothelial Cell Loss



Endothelial Cell Loss – Mechanisms

- Risk: Surgical manipulation and potential contact with ICL
- Monitoring: Specular microscopy to track cell density

Endothelial cell loss post-implantable collamer lens V4c: meta-analysis



Filip Blazej Kisiel, MEng, Gerard Jonathan Gurumurthy, MBChB

Endothelial cell density (ECD) loss is a noted effect of implantable collamer lens (ICL) V4c surgery. Current literature provides a wide range of values for ECD loss postsurgery, which may not be helpful in advising patients and clinicians. A meta-analysis exploring ECD loss in ICL V4c for myopia correction was undertaken. 18 studies were included in this meta-analysis with 2 subgroup analyses to account for the variability in follow-up lengths. The average ECD loss 3 months, 12 months, and 21.25 (mean) months postsurgery were $1.32\% \pm 1.28\%$ ($P < .001$, 95% CI, -75.158 to -1.19), $1.75\% \pm 2.17\%$

($P < .001$, 95% CI, -134.09 to 14.52), and $3.84\% \pm 1.78\%$ ($P < .001$, 95% CI, -156.04 to -54.26), respectively. ECD loss is most pronounced 3 months postsurgery, suggesting that acute surgical trauma was the primary contributor rather than long-term lens implantation. Overall, ICL V4c for myopia correction exhibits similar ECD loss as seen in other ICL models, thereby affirming its safety.

J Cataract Refract Surg 2024; 50:420–423 Copyright © 2024 Published by Wolters Kluwer on behalf of ASCRS and ESCRS

Endothelial Cell Density

Reference	N (eyes)	N (subjects)	Follow Up	Change in Endothelial Cell Density
Lisa ¹ J Cataract Refract Surg 2015	147	80	1 year	-1.7%
Kamiya ² Br J Ophthalmol 2017 Group 1: MRSE < -6 D (n = 57) Group 2: MRSE ≥ -6 D (n = 294)	57 294	57 294	1 year	-0.1 ± 9.7% -0.1 ± 10.0%
Fernandez-Vega-Cueto ³ Clinical Ophthalmology 2018	184	92	3 years	-2.9%
Shimizu ⁴ Medicine (Baltimore) 2016	32	32	5 years	-0.5 ± 5.4% “no significant change”(p = 0.73)
Alfonso ⁵ J Refract Surg 2019	147	83	5 years	-0.43% “non-significant loss” (p = 0.304)

1. Lisa et al. Posterior chamber collagen copolymer phakic intraocular lens with a central hole to correct myopia: One-year follow-up. J Cataract Refract Surg 2015; 41: 1153-1159.

2. Kamiya et al. Posterior chamber phakic intraocular lens implantation: comparative, multicentre study in 351 eyes with low-to-moderate or high myopia. Br J Ophthalmol 2018;102:177–181.

3. Fernández-Vega-Cueto, L et al Implantable collamer lens with central hole: 3-year follow-up. Clinical Ophthalmology 2018;12 2015–2029.

4. Shimizu et al. Long-Term Comparison of Posterior Chamber Phakic Intraocular Lens With and Without a Central Hole (Hole ICL and Conventional ICL) Implantation for Moderate to High Myopia and Myopic Astigmatism: Consort-Compliant Article. Medicine (Baltimore). 2016 Apr; 95(14): e3270.

5. Alfonso et al. Five-year follow-up of correction of myopia: Posterior chamber phakic intraocular lens with a central port design. J Refract Surg. 2019;35(3):169-176

Endothelial Cell Loss – Impact on Corneal Health

- Reduced cell density may lead to corneal decompensation
- Long-term safety: Minimal ongoing loss if proper vault is maintained

Endothelial Cell Loss – Preventative Measures

- Accurate ICL sizing for proper vault
- Meticulous surgical technique
- Regular post-op monitoring



INTERNATIONAL CONGRESS OF THE
EGYPTIAN
OPHTHALMOLOGICAL SOCIETY

In collaboration with:



MEACO
MIDDLE EAST AFRICA
COUNCIL OF OPHTHALMOLOGY

Lens Related Issues



Lens-Related Issues – Positioning & Rotation


- Risks: Incorrect vault (excessive or insufficient)
- Toric ICLs: Risk of rotation affecting astigmatic correction
- Management: Repositioning if significant rotation occurs

Adequate vault ranges 90 to 1,000 microns ^{1,2}

Ideal vault range 250 – 750 microns ⁴

Weak correlation between WTW and STS values ^{2,3}

1. Gonvers M, Bornet C, Othein-Girard P. Implantable Contact Lens for Moderate to High Myopia; relationship of vaulting to cataract formation. J Cataract Refract Surg 2003; 29:918-924
2. Dougherty PJ, Rivera RP, Schnieder D, Lane SS, Brown D, Vukich J. Improving accuracy of phakic intraocular lens sizing using high-frequency ultrasound biomicroscopy. J Cataract Refract Surg 2010; 37: 13-18.
3. Reinstein DZ, Archer TJ, Silverman RH, Rondeau MJ, Coleman DJ. Correlation of anterior chamber angle and ciliary sulcus diameters with white-to-white corneal diameter in high myopes using Artemis VHF digital ultrasound. J Refract Surg 2009; 25: 185-194.
4. Alfonso JF, Fernandez-Vega, L, Lisa C, Fernandes P, Jorge J, Montes-Mico R. Central Vault after phakic intraocular lens implantation: Correlation with anterior chamber depth, white-to-white distance, spherical equivalent, and patient age. J Cataract Refract Surg 2012; 38:46-53



Lens-Related Issues – Positioning & Rotation




Figure 1. Reasons for explantations in 1,490 eyes with posterior chamber phakic intraocular lens (PCO IOL) implantation.




Figure 1. Incidence and causes of ICL realignment or exchange after EVO-ICL implantation (eyes). TICL = toric ICL.

1. Alió JL, Toffaha BT, Peña-García P, Sádaba LM, Barraquer RI. Phakic intraocular lens explantation: causes in 240 cases. *J Refract Surg.* 2015;31(1):30-35. doi:10.3928/1081597X-20141202-01
2. Galvis V, Tello A, Cuadros MO, Carreño NI, Berrospi RD, Niño CA. Causes of Explanation of Phakic Intraocular Lenses. *J Refract Surg.* 2015;31(8):566-567. doi:10.3928/1081597X-20150728-04
3. Zeng QY, Xie XL, Chen Q. Prevention and management of collagen copolymer phakic intraocular lens exchange: causes and surgical techniques. *J Cataract Refract Surg.* 2015;41(3):576-584. doi:10.1016/j.jcrs.2014.06.036
4. AlSabaani NA, Behrens A, Jastanieh S, Al Malki S, Al Jindan M, Al Motowa S. Causes of Phakic Implantable Collamer Lens Explanation/Exchange at King Khaled Eye Specialist Hospital. *Middle East Afr J Ophthalmol.* 2016;23(4):293-295. doi:10.4103/0974-9233.194076
5. Kaur M, Titilay JS, Falera R, Sinha R, Sharma N. Indications for explant of implantable collamer lens. *Eye (Lond).* 2018;32(4):838-840. doi:10.1038/eye.2017.307
6. Alhamzah A, Alharbi SS, Alfardan F, Aldebasi T, Almudhaiyan T. Indications for exchange or explantation of phakic implantable collamer lens with central port in patients with and without keratoconus. *Int J Ophthalmol.* 2021;14(11):1714-1720. doi:10.18240/ijo.2021.11.10
7. Sucu ME, Cakmak S, Yildirim Y, Yildiz BK, Yalçinkaya G, Beşek NK, Yasar T. Explanation of phakic intraocular lenses: causes and outcomes. *Int Ophthalmol.* 2021;41(1):265-271. doi:10.1007/s10792-020-01578-z
8. Yildirim TM, Khoramnia R, Son HS, Mayer CS, Labuz G, Munro DJ, Auffarth GU. Reasons for explantation of phakic intraocular lenses and associated perioperative complications: cross-sectional explant registry analysis. *BMC Ophthalmology.* 2021;21(1):80. doi:10.1186/s12886-021-01847-0
9. Marques JH, Baptista PM, Abreu AC, Monteiro S, Pinto M do C. Phakic intraocular lens explantation: a series of 175 surgeries. *J Cataract Refract Surg.* Published online February 25, 2022. doi:10.1097/j.jcrs.0000000000000920
10. Wei R, Li M, Aruma A, Knorz MC, Yang D, Yu Y, Wang X, Choi J, Yao P, Zhou X. Factors leading to re-alignment or exchange after ICL implantation in 10,258 eyes. *J Cataract Refract Surg.* Published online March 29, 2022. doi:10.1097/j.jcrs.0000000000000950
11. Coskunseven E, Kayhan B. Reasons for Explantations of Posterior Chamber Phakic Intraocular Lenses in 1,490 Eyes. *J Refract Surg.* 2024;40(11):e797-e803. doi:10.3928/1081597X-20240913-03

Refractive Enhancement – Introduction

- Secondary procedure to fine-tune residual refractive error
- Rationale: Achieve optimal visual acuity



Patient Assessment for Refractive Enhancement

- Evaluation: Stable refraction, corneal thickness, patient symptoms
- Consider enhancement if residual error >0.75 D

Timing of Enhancement Procedures

- Wait at least 3 months post-ICL for stability
- Ensures full healing before enhancement

Techniques for Refractive Enhancement

- Options: Excimer laser (LASIK/PRK), ICL exchange, repositioning
- Laser is less invasive; exchange for larger errors

Laser-Assisted Enhancements – PRK & LASIK Considerations

- Advantages: Precise correction
- Consider corneal thickness and healing response

Lens Exchange vs. Refractive Enhancement

- Decision factors: Residual error, patient preference, corneal suitability
- Exchange is more invasive than a laser touch-up


Visual Disturbances – Halos and Glare

- Causes: Lens design, post-op healing variations
- Mitigation: Proper lens placement and potential enhancements

Optical studies of the EVO ICL have demonstrated that the presence of the central port does not compromise the optical quality of the image as measured by MTF, wavefront aberrometry, or adaptive optics simulation.

One study has shown that reflected stray light from eccentric sources may result in positive dysphotopsia

1. Packer M. The Implantable Collamer Lens with a central port: review of the literature. *Clin Ophthalmol*. 2018;12:2427-2438.
doi:10.2147/OPTH.S188785



Optical Effects

Authors	Finding
Shimizu et al	Provided data on higher order aberrations and contrast sensitivity . Found that the central port had no significant impact .
Kamiya et al	EVO implantation appears to be essentially equivalent in the optical quality variables to conventional ICL implantation. Suggesting that the presence of the central artificial hole does not significantly affect the optical quality and the intraocular scattering after surgery.
Huseynova et al	Reported no significant differences in wavefront aberrations between EVO and conventional ICL subjects.

QUALITY OF VISION

- Prospective studies ^{1, 2} have been conducted comparing outcomes between subjects implanted with V4c (EVO) and V4b (ICL without central hole):
 - ▢ Higher Order Aberrations (HOAs)
 - ▢ Contrast Sensitivity (photopic, mesopic and mesopic with glare)
 - ▢ Subjective Symptoms (glare, halo)
- Quality of vision was equivalent between the V4c (EVO) and V4b (ICL without central hole) models

1. Shimizu K, Kamiya K, Igarashi A, Shiratani T. Intraindividual comparison of visual performance after posterior chamber phakic intraocular lens with and without a central hole implantation for moderate to high myopia. Am J Ophthalmol. 2012 Sep;154(3):486-494.
2. Kamiya K, Shimizu K, Saito A, Igarashi A, Kobashi H. Comparison of optical quality and intraocular scattering after posterior chamber phakic intraocular lens with and without a central hole (Hole ICL and Conventional ICL) implantation using the double-pass instrument. PLoS One. 2013 Jun 25;8(6):e66846.

Dysphotopsia – Overview & Patient Experience

- Definition: Unwanted visual phenomena (halos, glare)
- Often transient but can affect quality of vision

Ring-shaped dysphotopsia associated with posterior chamber phakic implantable collamer lenses with a central hole

Youngsub Eom,¹ Dae Wook Kim,² Dongok Ryu,^{3,4,5} Jun-Heon Kim,⁶ Seul Ki Yang,^{3,4,5} Jong Suk Song,¹ Sug-Whan Kim^{3,4,5} and Hyo Myung Kim¹

¹Department of Ophthalmology, Korea University College of Medicine, Seoul, South Korea

²College of Optical Sciences, University of Arizona, Tucson, Arizona, USA

³Space Optics Laboratory, Department of Astronomy, Yonsei University, Seoul, South Korea

⁴Center for Galaxy Evolution Research, Yonsei University, Seoul, South Korea

⁵Yonsei University Observatory, Yonsei University, Seoul, South Korea

⁶Jocheon Vision Clinic, Seoul, South Korea

Visual Disturbances – Optical Considerations

- ICLs typically provide high contrast sensitivity
- Modern designs minimize unwanted visual effects

Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life



ELENA MARTÍNEZ-PLAZA, ALBERTO LÓPEZ-MIGUEL, ALBERTO LÓPEZ-DE LA ROSA, COLM MCALINDEN,
ITZIAR FERNÁNDEZ, AND MIGUEL J. MALDONADO

• **CONCLUSIONS:** EVO+ implantation provides good mesopic visual performance, QoV, and QoL during up to 6 months follow-up. Some activities performed under mesopic conditions with glare sources may be affected during the first postoperative week. Ring-shaped dysphopia is negligibly bothersome 6 months after surgery.

Dysphotopsia – Overview & Patient Experience

- Definition: Unwanted visual phenomena (halos, glare)
- Often transient but can affect quality of vision

Ring-shaped dysphotopsia associated with posterior chamber phakic implantable collamer lenses with a central hole

Youngsub Eom,¹ Dae Wook Kim,² Dongok Ryu,^{3,4,5} Jun-Heon Kim,⁶ Seul Ki Yang,^{3,4,5} Jong Suk Song,¹ Sug-Whan Kim^{3,4,5} and Hyo Myung Kim¹

¹Department of Ophthalmology, Korea University College of Medicine, Seoul, South Korea

²College of Optical Sciences, University of Arizona, Tucson, Arizona, USA

³Space Optics Laboratory, Department of Astronomy, Yonsei University, Seoul, South Korea

⁴Center for Galaxy Evolution Research, Yonsei University, Seoul, South Korea

⁵Yonsei University Observatory, Yonsei University, Seoul, South Korea

⁶Jocunna Vision Clinic, Seoul, South Korea

Dysphotopsia – Management & Counseling

- Reassurance: Usually improves over time
- Options: Optical aids or enhancements for severe cases

Monitoring Protocols Post-ICL

- Recommended schedule: Day 1, Week 1, Month 1, then periodic reviews
- Monitor IOP, inflammation, lens position, endothelial count

Pharmacological Management Post-ICL

- Medications: IOP-lowering drops, topical steroids, NSAIDs
- Tailor therapy based on complications (e.g., steroid response)

Role of Steroids in Managing Inflammation

- High-frequency dosing initially, then gradual taper
- Monitor for steroid-induced IOP rise

Role of IOP-Lowering Agents

- Options: Beta-blockers, prostaglandin analogs, carbonic anhydrase inhibitors
- Rapid reduction of IOP during spikes

Surgical Interventions for Complications

- Indications: Uncontrolled IOP, significant lens malposition
- Options: Anterior chamber washout, ICL repositioning/exchange

Predictive Factors for Post-Op Complications

- Factors: Patient age, degree of myopia, anatomical measurements
- Pre-operative risk stratification minimizes complications

Risk Stratification & Patient Selection


- Detailed screening: WTW, AC depth, endothelial count
- Better outcomes with proper patient selection

Preoperative Assessment and Optimization

- Comprehensive ocular exam and patient education
- Optimize outcomes and minimize risks

Enhancing Outcomes – Surgical Technique Refinements

- Innovations: Improved lens design (e.g., EVO ICL), minimal OVD techniques
- Lower complication rates and improved long-term outcomes



RESEARCH

Open Access

Clinical observations of EVO-ICL implantation and changes in corneal astigmatism using a modified technique

Ying Wang, Ruibo Yang, Yue Huang, Chen Zhang, Hui Liu, Zhe Jia and Shaozhen Zhao*



One-year Observation of Safety of Implantable Collamer Lens V4c Implantation Without Using an Ophthalmic Viscosurgical Device

Zhuoqi Chen^{1,2,3,4*}, Lingling Wu^{1,2,3,4}, Jing Zhao^{1,2,3,4}, Peijun Yao^{1,2,3,4}, Xiaoying Wang^{1,2,3,4} and Xingtao Zhou^{1,2,3,4}

¹Department and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China; ²Department of Ophthalmology, Shanghai Eye & ENT Hospital, Shanghai, China; ³Shanghai Institute of Ophthalmology and Optics, Shanghai, China; ⁴Shanghai Institute of Ophthalmology and Optics, Shanghai, China

EOS 2025

EGYPTIAN OPHTHALMOLOGICAL SOCIETY

22/06/2025

Post-Operative Patient Education & Counseling

- Topics: Warning signs, medication adherence, follow-up schedule
- Early detection leads to better management

Follow-Up Regimens and Timing

- Schedule: Day 1, Week 1, Month 1, then periodic reviews
- Focus: IOP, inflammation, lens position

Recent Advances in ICL Technology

- Innovations: Central port designs, toric models, improved materials
- Benefits: Reduced complications and enhanced visual quality



Comparative Studies – ICL vs. Other Refractive Surgeries

- ICL outcomes compared to LASIK/PRK in high myopes
- ICL offers excellent vision quality, especially for extreme prescriptions

RESEARCH

Open Access

Quality of vision after myopic refractive surgeries: SMILE, FS-LASIK, and ICL



Huiyi Du¹, Bo Zhang¹, Zheng Wang¹ and Lu Xiong^{1*}

Conclusions SMILE, FS-LASIK, and ICL had comparable visual outcomes. Overall, glare, fluctuation in vision, and halos were the most frequently experienced visual symptoms 3 months postoperatively. Patients with ICL implanted tended to report halos more frequently compared with SMILE and FS-LASIK. Mesopic pupil size, postoperative UDVA, and postoperative residual myopic sphere were predicted factors for reported visual symptoms.

EOS 2025

EGYPTIAN OPHTHALMOLOGICAL SOCIETY

22/06/2025

A NEW REFRACTIVE SURGERY PARADIGM IS EMERGING

Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism¹

- Patients having either **EVO Toric, FS-LASIK or ReLEx SMILE**
- 30 eyes of 30 patients in each group
- 21 to 40 years of age
- **MRSE -3.00 to -8.00 D**
- Astigmatism ≥ -0.75 D.
- 1 year follow up

1. Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017;11:1253-63.

A NEW REFRACTIVE SURGERY PARADIGM IS EMERGING

Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism¹

“All 3 groups were comparable for UDVA, DCVA, SE and Cyl correction”

EVO Toric ICL demonstrated:

- Highest efficacy index (post-op UCVA/pre-op CDVA: 1.12)
- Highest safety index (post-op CDVA/pre-op CDVA: 1.24)
- No significant change in endothelial cell density

1. Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017;11:1253-63.

A NEW REFRACTIVE SURGERY PARADIGM IS EMERGING


Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism¹

EVO Toric ICL demonstrated:

- “Postoperative dry eye was least with T-ICL” (EVO Toric)
- Improvement in contrast sensitivity
 - “Significantly Better ($p < 0.05$)” when compared to ReLEx SMILE and FS-LASIK”
- “Significant improvement” (reduction) in higher order aberrations”
 - HOAs increased with ReLEx SMILE (marginal, not significant ($p = 0.68$)) and FS-LASIK (significant ($p = 0.038$))
- “Patients reported excellent satisfaction with their quality of vision”

Summary of Key Points

- ICLs provide outstanding refractive correction for high myopes
- Short-term complications are manageable with early detection
- Refractive enhancements (bioptics) fine-tune outcomes
- Emphasis on pre-operative planning, precise technique, and follow-up



Final Recommendations for Surgeons

- Pre-operative diligence, accurate ICL sizing, vigilant monitoring
- Inform patients about possible enhancements if needed

Do You Have Any Questions ?



- www.hypervision.gr



- georgiosroussopoulos@gmail.com

- +30 694 475 3486



- Georgios Roussopoulos (English)
- Γεώργιος Ρουσσόπουλος (Greek)

EOS 2025

EGYPTIAN OPHTHALMOLOGICAL SOCIETY

22/06/2025



INTERNATIONAL CONGRESS OF THE
EGYPTIAN
OPHTHALMOLOGICAL SOCIETY

In collaboration with:



MEACO
MIDDLE EAST AFRICA
COUNCIL OF OPHTHALMOLOGY

THANK YOU FOR YOUR ATTENTION

